Publication | Closed Access

Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model

NanoparticlesNanomedicineNeuro-oncologyDrug TargetingEngineeringTherapeutic NanomaterialsMedicineGlioblastoma Tumor RegressionNano-drug DeliveryTumor TargetingLiposomal NanoparticlesRadiation OncologyPharmacologyGliomaTumor Microenvironment